Padeliporfin

Drug Overview

Padeliporfin (marketed under the brand name Tookad®) is an investigational, water-soluble, palladium-substituted photosensitizer derived from bacteriochlorophyll. It is the core component of Vascular-Targeted Photodynamic Therapy (VTP), a minimally invasive focal treatment designed to ablate solid tumors while preserving surrounding healthy tissue.

In the clinical landscape of March 2026, padeliporfin is recognized for its unique “vascular-acting” mechanism. Unlike traditional photodynamic therapies that target cancer cells directly, padeliporfin remains strictly within the blood vessels. When activated by a specific wavelength of low-power laser light (753 nm), the drug triggers the local production of reactive oxygen species (ROS). This causes immediate vascular occlusion—effectively “choking off” the tumor’s blood supply—and leads to targeted necrosis. Originally approved by the EMA in 2017 for low-risk prostate cancer, padeliporfin is currently the subject of the pivotal Phase 3 ENLIGHTED trial for upper tract urothelial carcinoma (UTUC). Recent interim data from late 2025 have shown high complete response rates, positioning it as a potential organ-sparing breakthrough for patients who would otherwise face kidney removal.

• Generic Name: Padeliporfin (as di-potassium salt).
• Brand Name: Tookad®.
• Code Name: WST11.
• Drug Class: Photosensitizing Agent; Antineoplastic.
• Mechanism: Light-activated generation of ROS leading to vascular occlusion and tumor necrosis.
• Route of Administration: Intravenous (IV) infusion followed by laser illumination.
• FDA Approval Status: Investigational/Fast Track. While EMA-approved for prostate cancer, it is currently in Phase 3 trials in the U.S. for UTUC and has received Fast Track and Orphan Drug designations for various indications.

What Is It and How Does It Work? (Mechanism of Action)

Padeliporfin works through a highly localized, light-triggered chemical reaction that destroys the “infrastructure” of a tumor.

1. The Photosensitizer “Fuel”

Padeliporfin is a palladium-based chlorophyll derivative that is inactive until it meets a specific frequency of light. Following IV administration, it circulates in the blood but does not leak out into healthy tissues.

2. Laser Activation

Precisely 10 minutes after the infusion, a near-infrared laser (753 nm) is activated. The light is delivered via thin optical fibers inserted directly into or near the tumor (e.g., through a scope into the kidney or transperineally into the prostate).

• ROS Generation: The light energy reacts with the drug and dissolved oxygen in the blood to create superoxide and hydroxyl radicals.
• Vascular Occlusion: These radicals damage the lining of the tumor’s blood vessels, causing them to clot and close instantly.

3. “Self-Propagating” Necrosis

Because the blood supply is cut off, the tumor cells die from a lack of oxygen and nutrients.

• Immune Activation: Preclinical and clinical studies in 2025 suggest that this rapid cell death releases tumor antigens, which may help the body’s immune system recognize and attack remaining cancer cells—a process known as the abscopal effect.

Clinical Indications and Research Status (2026)

In 2026, padeliporfin is being pushed beyond its original use in the prostate to treat “unresectable” or organ-specific cancers:

• Low-Grade Upper Tract Urothelial Carcinoma (UTUC): The Phase 3 ENLIGHTED trial (NCT04620239) reported updated results in December 2025, showing a 70% Complete Response (CR) rate in patients. It is being studied as a way to avoid radical nephroureterectomy (kidney removal).
• Localized Prostate Cancer: Approved in Europe for “low-risk” adenocarcinoma. It is utilized for focal ablation to minimize side effects like incontinence and erectile dysfunction.
• Unresectable Pancreatic Adenocarcinoma: A Phase 1 trial (NCT05919238) was updated in February 2026, investigating VTP as a way to debulk tumors that cannot be surgically removed.
• Non-Small Cell Lung Cancer (NSCLC): In March 2026, the FDA cleared a Phase 1 trial for robotic-assisted bronchoscopic ablation of peripheral lung tumors.

Dosage and Administration Protocols

Padeliporfin treatment is a highly technical procedure performed under anesthesia in an “induction” and “maintenance” phase.

Safety Profile and Side Effects

The side effects of padeliporfin are usually localized to the treatment area and the procedural instrumentation.

1. Photosensitivity (Light Sensitivity)

Because the drug is light-sensitive, patients must avoid direct sunlight and bright indoor lights for a short period (usually 12–24 hours) after treatment.

• Management: Protective clothing and “dimmed” environments are required.

2. Common Side Effects (>20%):

• Urological Issues: Flank pain, hematuria (blood in urine), and dysuria (painful urination) are common following kidney or prostate treatment.
• Procedural Pain: Most events are Grade 1–2 and resolve within 2 to 7 days.

3. Serious Risks:

• Renal Colic: Observed in roughly 9% of UTUC patients in the ENLIGHTED trial.
• Sexual Dysfunction: While lower than with surgery, risk of erectile dysfunction still exists in prostate treatments.
• Hepatotoxicity: Occasional, temporary increases in liver enzymes (ALT/AST).

Research Areas

In the fields of Stem Cell and Regenerative Medicine, padeliporfin is a model for studying “Selective Ablation.” Researchers are investigating how VTP can be used to “clear” a diseased organ niche to prepare it for Stem Cell Transplantation. In 2026, there is also intense focus on “VTP-guided Nanotherapy,” where VTP is used to “open” the tumor environment to allow high concentrations of targeted nanoparticles to enter and remain in the tumor for weeks.

Patient Management and Practical Recommendations

Pre-treatment Requirements:

• Imaging: High-resolution CT or ultrasound to map the exact tumor coordinates.
• Skin Check: Assessment for any pre-existing light sensitivities.

“Do’s and Don’ts” List:

• DO stay in a “dimmed light” environment for at least 24 hours; use incandescent bulbs (60W max) and avoid LEDs or fluorescent lights for the first 6 hours.
• DO wear sunglasses and high-protection goggles if you must go outdoors immediately following the procedure.
• DON’T ignore sudden “pounding flank pain” or inability to urinate, as these could be signs of a temporary blockage from the ablation.
• DON’T apply any topical “photosensitizing” creams (like certain acne treatments) for at least a week before the procedure.

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Padeliporfin (Tookad) is currently an investigational agent in the U.S. for UTUC and pancreatic cancer. Its use is restricted to clinical trials or approved indications in specific international jurisdictions. Always consult with a board-certified urologist or oncologist regarding focal therapy options and clinical trial eligibility.